Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Explorative study of AZD4831 in pulmonary arterial hypertension
2020-002788-80Phase 2Completed
- Sponsor
- University of Cologne
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of mitiperstat in pulmonary arterial hypertension (PAH), pulmonary hypertension (PH) and pulmonary hypertension due to left heart disease (PH-LHD) (2 arms), sponsored by University of Cologne. Primary endpoint: Change in pulmonary vascular resistance. Started Jun 2020; status: completed.
02
Drugs
mitiperstat
03
Conditions
pulmonary arterial hypertension (PAH)pulmonary hypertension (PH)pulmonary hypertension due to left heart disease (PH-LHD)
Beyond the preview
Go deeper on 2020-002788-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002788-80.